Safety,efficiency and cost effectiveness of Bivalirudin:A systematic review

作     者：Melorin Mehrzad Rasikh Tuktamyshov Raman Mehrzad 

作者机构：Department of Internal MedicineYale New Haven HospitalYale School of medicineNew HavenCT 06510United States 

出 版 物：《World Journal of Cardiology》 (世界心脏病学杂志（英文版）（电子版）)

年 卷 期：2017年第9卷第9期

页      面：761-772页

学科分类：1007[医学-药学(可授医学、理学学位)] 1006[医学-中西医结合] 100706[医学-药理学] 1002[医学-临床医学] 100602[医学-中西医结合临床] 10[医学] 

主　　题：Efficiency Cost effectiveness Bivalirudin Safety 

摘      要：AIM To review the early and more recent studies of Bivalirudin, to assess the safety, effectiveness, and cost benefits of this *** Literature search of MEDLINE and Pub Med databases from 1990 to 2017 using keywords as bivalirubin and angiomax, combined with the words safety, effectiveness, efficiency, side effects, toxicity, adverse effect, and adverse drug reaction.RESULTS A total of 66 publications were reviewed. The changes in clinical practice and differences in clinical protocols make it difficult to do direct comparisons of studies among each other. However, most trials showed decreased bleeding complications with bivalirudin, although ischemic complications and mortality were mostly comparable, with some favor towards *** Bivalirudin and heparin are both acceptable options according to current ACA/AHA guidelines. Authors conclude however, that that due to bivalirudin safer bleeding profile, it should be the preferred medication for anticoagulation.